Abb Knockout/Transgenic HLA-DR4 Related Publications

Blazanovic K, Zhao H, Choi Y, Li W, Salvat RS, Osipovitch DC, Fields J, Moise L, Berwin BL, Fiering SN, Bailey-Kellogg C, Griswold KE. (2015) Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance. Mol Ther Methods Clin Dev. 2:15021.

Brentville VA, Metheringham RL, Gunn B, Symonds P, Daniels I, Gijon M, Cook K, Xue W, Durrant LG. (2016) Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity. Cancer Res. 76(3):548-60.

Brentville VA, Metheringham RL, Gunn B, Symonds P, Daniels I, Gijon M, Xue W, Durrant LG. CD4 T cells targeting citrullinated vimentin reject advanced tumors. American Association for Cancer Research Annual Meeting (AACR 2015), April 18-22, 2015, Philadelphia, PA, USA.

Brentville VA, Xue W, Symonds P, Cook K, Gunn B, Metheringham R, Durrant L. Adjuvant choice modulates self antigen specific CD4 responses generated by peptide vaccination. 15th International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6-8 October 2015, Tübingen, Germany.

Call MJ, Xing X, Cuny GD, Seth NP, Altmann DM, Fugger L, Krogsgaard M, Stein RL, Wucherpfennig KW. (2009) In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol. 182(10):6342-52.

Cook K, Daniels I, Brentville V, Metheringham R, Xue W, Symonds P, Pitt T, Gijon M, Durrant L. Anti-tumour immune responses to citrullinated enolase. 15th International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6-8 October 2015, Tübingen, Germany.

Greidinger EL, Zang YJ, Jaimes K, Martinez L, Nassiri M, Hoffman RW. (2008) CD4+ T cells target epitopes residing within the RNA-binding domain of the U1-70-kDa small nuclear ribonucleoprotein autoantigen and have restricted TCR diversity in an HLA-DR4-transgenic murine model of mixed connective tissue disease. J Immunol. 180(12):8444-54.

Grusby MJ, Johnson RS, Papaioannou VE, Glimcher LH. (1991) Depletion of CD4+ T Cells in Major Histocompatibility Complex Class II - Deficient Mice. Science. 253(5026):1417-20.

Hayworth JL, Kasper KJ, Leon-Ponte M, Herfst CA, Yue D, Brintnell WC, Mazzuca DM, Heinrichs DE, Cairns E, Madrenas J, Hoskin DW, McCormick JK, Haeryfar SM. (2009) Attenuation of massive cytokine response to the staphylococcal enterotoxin B superantigen by the innate immunomodulatory protein lactoferrin. Clin Exp Immunol. 157(1):60-70.

Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, Robinson WH, Cairns E. (2008) Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med. 205(4):967-79.

Hill JA, Wang D, Jevnikar AM, Cairns E, Bell DA. (2003) The relationship between predicted peptide-MHC class II affinity and T cell activation in a HLA-DRbeta1*0401 transgenic mouse model. Arthritis Res Ther. 5(1):R40-8.

Iliopoulou BP, Alroy J, Huber BT. (2008) Persistent arthritis in Borrelia burgdorferi-infected HLA-DR4-positive CD28-negative mice post-antibiotic treatment. Arthritis Rheum. 58(12):3892-901.

Ito K, Bian HJ, Molina M, Han J, Magram J, Saar E, Belunis C, Bolin DR, Arceo R, Campbell R, Falcioni F, Vidović D, Hammer J, Nagy ZA. (1996) HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis, J Exp Med. 183(6):2635-44.

James EA, Rieck M, Pieper J, Gebe JA, Yue BB, Tatum M, Peda M, Sandin C, Klareskog L, Malmström V, Buckner JH. (2014) Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol. 66(7):1712-22.

Kawamura K, McLaughlin KA, Weissert R, Forsthuber TG. (2008) Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice. J Immunol. 181(5):3202-11.

Khan AM, Miotto O, Nascimento EJ, Srinivasan KN, Heiny AT, Zhang GL, Marques ET, Tan TW, Brusic V, Salmon J, August JT. (2008) Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis. 2(8):e272.

Kim H, Darwish I, Monroy MF, Prockop DJ, Liles WC, Kain KC. (2014) Mesenchymal stromal (stem) cells suppress pro-inflammatory cytokine production but fail to improve survival in experimental staphylococcal toxic shock syndrome. BMC Immunol. 15:1.

Klucar P, Barnes PF, Kong Y, Howard ST, Pang X, Huang FF, Tvinnereim AR, Samten B, Shams H. (2009) Vaccination strategies to enhance local immunity and protection against Mycobacteriun tuberculosis. Vaccine. 27(12):1816-24.

Meyer AL, Trollmo C, Crawford F, Marrack P, Steere AC, Huber BT, Kappler J, Hafler DA. (2000) Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci USA. 97(21):11433-8.

Murthy AK, Cong Y, Murphey C, Guentzel MN, Forsthuber TG, Zhong G, Arulanandam BP. (2006) Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun. 74(12):6722-9.

Musson JA, Reynolds CJ, Rinchai D, Nithichanon A, Khaenam P, Favry E, Spink N, Chu KK, De Soyza A, Bancroft GJ, Lertmemongkolchai G, Maillere B, Boyton RJ, Altmann DM, Robinson JH. (2014) J Immunol. 193(12):6041-9.

Rojas JM, McArdle SE, Horton RB, Bell M, Mian S, Li G, Ali SA, Rees RC. (2005) Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53. Cancer Immunol Immunother. 54(3):243-53.

Scally SW, Petersen J, Law SC, Dudek NL, Nel HJ, Loh KL, Wijeyewickrema LC, Eckle SB, van Heemst J, Pike RN, McCluskey J, Toes RE, La Gruta NL, Purcell AW, Reid HH, Thomas R, Rossjohn J. (2013) A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med. 210(12):2569-82.

Sloan JM, Kershaw MH, Touloukian CE, Lapointe R, Robbins PF, Restifo NP, Hwu P. (2002) MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Ther. 9(11):946-50.

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, Platten M. (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 512(7514):324-7.

Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP. (2000) Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 164(7):3535-42.

Walker KM, Rytelewski M, Mazzuca DM, Meilleur SA, Mannik LA, Yue D, Brintnell WC, Welch I, Cairns E, Haeryfar SM. (2012) Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist. Immunol Cell Biol. 90(6):630-9.

Wijayalath W, Majji S, Kleschenko Y, Pow-Sang L, Brumeanu TD, Villasante EF, Vasta GR, Fernández-Robledo JA, Casares S. (2014) Humanized HLA-DR4 mice fed with the protozoan pathogen of oysters Perkinsus marinus (Dermo) do not develop noticeable pathology but elicit systemic immunity. PLoS One. 9(1):e87435.

Wijayalath W, Danner R, Kleschenko Y, Majji S, Villasante EF, Richie TL, Brumeanu TD, David CS, Casares S. (2014) HLA class II (DR0401) molecules induce Foxp3+ regulatory T cell suppression of B cells in Plasmodium yoelii strain 17XNL malaria. Infect Immun. 82(1):286-97.

Willett TA, Meyer AL, Brown EL, Huber BT. (2004) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc Natl Acad Sci USA. 101(5):1303-8.

Xu SX, Kasper KJ, Zeppa JJ, McCormick JK. (2015) Superantigens Modulate Bacterial Density during Staphylococcus aureus Nasal Colonization. Toxins (Basel). 7(5):1821-36.

Xu SX, Gilmore KJ, Szabo PA, Zeppa JJ, Baroja ML, Haeryfar SM, McCormick JK. (2014) Superantigens subvert the neutrophil response to promote abscess formation and enhance Staphylococcus aureus survival in vivo. Infect Immun. 82(9):3588-98.

Xue W, Brentville V, Metheringham R, Cook K, Symonds P, Daniel I, Durrant L. SCIB1 DNA vaccination synergises with PD-1 blockade to induce efficient tumor therapy of poorly immunogenic tumors. 15th International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6-8 October 2015, Tübingen, Germany.

Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. (2010) Francisella tularensis T cell antigen identification using humanized HLA-DR4 transgenic mice. Clin Vaccine Immunol. 17(2):215-22.

Zang Y, Martinez L, Fernandez I, Pignac-Kobinger J, Greidinger EL. (2014) Conservation of pathogenic TCR homology across class II restrictions in anti-ribonucleoprotein autoimmunity: extended efficacy of T cell vaccine therapy. J Immunol. 192(9):4093-102.

Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. (2000) Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol. 165(2):1153-9.